A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma
Mené sur 13 patients atteints d’un carcinome urothélial de stade métastatique résistant aux sels de platine, cet essai de phase II évalue l’efficacité, du point de vue du taux de survie sans progression à 2 mois, et la toxicité du buparlisib
Background : The phosphatidyl 3?inositol kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway frequently is activated in patients with urothelial carcinoma (UC). In the current study, the authors performed a phase 2 study evaluating the efficacy of the pan?isoform class I PI3K inhibitor buparlisib in patients with platinum?refractory metastatic UC. Methods : Two cohorts were recruited: an initial genetically unselected cohort and a subsequent expansion cohort of patients with PI3K/Akt/mTOR pathway–altered tumors. The primary endpoint was the 2?month progression?free survival rate. A rate of ?80% was considered promising using a Simon 2?stage minimax design. Secondary endpoints included safety and correlation of markers of PI3K pathway activation with outcome. Results : Six of 13 evaluable patients within the initial cohort demonstrated stable disease and 1 demonstrated a partial response, which was below the cutoff of 9 patients required to proceed to stage 2. Three of the patients with stable disease and the patient with a partial response harbored somatic TSC1 alterations. Four patients subsequently were recruited onto an expansion cohort: 3 patients with TSC1 alterations and 1 patient with a PIK3CA?activating mutation. No patient achieved disease control at 8 weeks and accrual was halted. Of the 19 patients evaluable for toxicity, 17 demonstrated treatment?related toxicities, 2 of whom had to discontinue therapy. Conclusions : Buparlisib was found to demonstrate modest activity in patients with metastatic UC whose tumors harbored TSC1 loss of function alterations; however, this was not a robust predictor of response to buparlisib. The pattern of genetic coalterations likely influences drug sensitivity. Given the modest clinical activity and substantial toxicity of buparlisib, future trials of PI3K inhibitors in patients with UC should focus on isoform?selective PI3K inhibitors in genomically selected patients.
Cancer 2020